Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
Hand-out
Press Releases
November 12, 2024

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments

Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 millionAchieved positive topline trial results from pivotal trial with troriluzole in spinocerebellar ataxia (SCA)Troriluzole

bradford

The Bradford Era

Local & Social